tiprankstipranks
Advertisement
Advertisement
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
PremiumCompany AnnouncementsBioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
8M ago
BioVie price target adjusted to $12 from $6 at Brookline
Premium
The Fly
BioVie price target adjusted to $12 from $6 at Brookline
9M ago
BioVie Completes $10.4 Million Public Offering
Premium
Company Announcements
BioVie Completes $10.4 Million Public Offering
10M ago
BioVie Expands Board Amid Drug Development Momentum
PremiumCompany AnnouncementsBioVie Expands Board Amid Drug Development Momentum
11M ago
BioVie appoints Amy Chappell, Kameel Farag to board of directors
Premium
The Fly
BioVie appoints Amy Chappell, Kameel Farag to board of directors
11M ago
BioVie reports results from bezisterim Phase 3 NM101 study
Premium
The Fly
BioVie reports results from bezisterim Phase 3 NM101 study
11M ago
BioVie Approves Reverse Stock Split Authority
PremiumCompany AnnouncementsBioVie Approves Reverse Stock Split Authority
12M ago
BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial
Premium
The Fly
BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial
1y ago
BioVie to host KOL event on Phase 2 study of bezisterim
Premium
The Fly
BioVie to host KOL event on Phase 2 study of bezisterim
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100